Casein kinase II (CK2) as a therapeutic target for hematological malignancies

Chandrika Gowda, Mansi Sachdev, Sunil Muthusami, Malika Kapadia, Lidija Petrovic-Dovat, Melanie Hartman, Yali Ding, Chunhua Song, Jonathon L. Payne, Bihua Tan, Sinisa Dovat

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Background: Casein kinase II (CK2) is a pro-oncogenic protein, which is emerging as a promising therapeutic target in cancer. Recent studies have revealed an important role for CK2 in tumorigenesis. High levels of CK2 are noted in many malignancies including leukemia. Use of CK2 inhibitors in various malignancies including breast, prostate, and lung cancer are being tested. Although many CK2 inhibitors exist, only a few have emerged as selective inhibitors that are potent and effective. CX-4945 is a selective, orallybioavailable small molecule inhibitor, which has shown encouraging results in pre-clinical models of leukemia. Methods: In this review we will elaborate on the structure and physiological function of the CK2 protein as well as its role in cancer. We will review, in depth, the role of CK2 in leukemia and its mechanisms of tumorigenesis via phosphorylation of the tumor suppressor protein Ikaros. We will discuss both the importance of Ikaros in leukemia suppression and the restoration of Ikaros’ tumor suppressor function after CK2 inhibition by CX-4945 (a CK2-specific inhibitor). Results: CK2 is an oncogene that is overexpressed in hematological malignancies. In high risk Pre-B ALL, CK2 phosphorylates Ikaros tumor suppressor and promotes leukemogenesis. Inhibition of CK2 using CX4945 restores Ikaros function and leads to anti leukemic effects in vitro and in pre-clinical leukemia models. Conclusion: CK2 is an attractive target in treatment of various cancers. Currently only a few specific CK2 inhibitors are available. Preclinical studies using CK2 inhibitor, CX4945 in high risk pediatric leukemias have shown promising results and warrants further testing in other types of leukemia.

Original languageEnglish (US)
Pages (from-to)95-107
Number of pages13
JournalCurrent Pharmaceutical Design
Volume23
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Casein Kinase II
Hematologic Neoplasms
Leukemia
Neoplasms
Therapeutics
Carcinogenesis
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Tumor Suppressor Proteins
Oncogenes
Lung Neoplasms
Prostatic Neoplasms
Proteins
Phosphorylation
Pediatrics
Breast Neoplasms
5-(3-chlorophenylamino)benzo(c)(2,6)naphthyridine-8-carboxylic acid

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

Cite this

Gowda, Chandrika ; Sachdev, Mansi ; Muthusami, Sunil ; Kapadia, Malika ; Petrovic-Dovat, Lidija ; Hartman, Melanie ; Ding, Yali ; Song, Chunhua ; Payne, Jonathon L. ; Tan, Bihua ; Dovat, Sinisa. / Casein kinase II (CK2) as a therapeutic target for hematological malignancies. In: Current Pharmaceutical Design. 2017 ; Vol. 23, No. 1. pp. 95-107.
@article{dfb461fcf01247d784ae7510162034c5,
title = "Casein kinase II (CK2) as a therapeutic target for hematological malignancies",
abstract = "Background: Casein kinase II (CK2) is a pro-oncogenic protein, which is emerging as a promising therapeutic target in cancer. Recent studies have revealed an important role for CK2 in tumorigenesis. High levels of CK2 are noted in many malignancies including leukemia. Use of CK2 inhibitors in various malignancies including breast, prostate, and lung cancer are being tested. Although many CK2 inhibitors exist, only a few have emerged as selective inhibitors that are potent and effective. CX-4945 is a selective, orallybioavailable small molecule inhibitor, which has shown encouraging results in pre-clinical models of leukemia. Methods: In this review we will elaborate on the structure and physiological function of the CK2 protein as well as its role in cancer. We will review, in depth, the role of CK2 in leukemia and its mechanisms of tumorigenesis via phosphorylation of the tumor suppressor protein Ikaros. We will discuss both the importance of Ikaros in leukemia suppression and the restoration of Ikaros’ tumor suppressor function after CK2 inhibition by CX-4945 (a CK2-specific inhibitor). Results: CK2 is an oncogene that is overexpressed in hematological malignancies. In high risk Pre-B ALL, CK2 phosphorylates Ikaros tumor suppressor and promotes leukemogenesis. Inhibition of CK2 using CX4945 restores Ikaros function and leads to anti leukemic effects in vitro and in pre-clinical leukemia models. Conclusion: CK2 is an attractive target in treatment of various cancers. Currently only a few specific CK2 inhibitors are available. Preclinical studies using CK2 inhibitor, CX4945 in high risk pediatric leukemias have shown promising results and warrants further testing in other types of leukemia.",
author = "Chandrika Gowda and Mansi Sachdev and Sunil Muthusami and Malika Kapadia and Lidija Petrovic-Dovat and Melanie Hartman and Yali Ding and Chunhua Song and Payne, {Jonathon L.} and Bihua Tan and Sinisa Dovat",
year = "2017",
month = "1",
day = "1",
doi = "10.2174/1381612822666161006154311",
language = "English (US)",
volume = "23",
pages = "95--107",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

Casein kinase II (CK2) as a therapeutic target for hematological malignancies. / Gowda, Chandrika; Sachdev, Mansi; Muthusami, Sunil; Kapadia, Malika; Petrovic-Dovat, Lidija; Hartman, Melanie; Ding, Yali; Song, Chunhua; Payne, Jonathon L.; Tan, Bihua; Dovat, Sinisa.

In: Current Pharmaceutical Design, Vol. 23, No. 1, 01.01.2017, p. 95-107.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Casein kinase II (CK2) as a therapeutic target for hematological malignancies

AU - Gowda, Chandrika

AU - Sachdev, Mansi

AU - Muthusami, Sunil

AU - Kapadia, Malika

AU - Petrovic-Dovat, Lidija

AU - Hartman, Melanie

AU - Ding, Yali

AU - Song, Chunhua

AU - Payne, Jonathon L.

AU - Tan, Bihua

AU - Dovat, Sinisa

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: Casein kinase II (CK2) is a pro-oncogenic protein, which is emerging as a promising therapeutic target in cancer. Recent studies have revealed an important role for CK2 in tumorigenesis. High levels of CK2 are noted in many malignancies including leukemia. Use of CK2 inhibitors in various malignancies including breast, prostate, and lung cancer are being tested. Although many CK2 inhibitors exist, only a few have emerged as selective inhibitors that are potent and effective. CX-4945 is a selective, orallybioavailable small molecule inhibitor, which has shown encouraging results in pre-clinical models of leukemia. Methods: In this review we will elaborate on the structure and physiological function of the CK2 protein as well as its role in cancer. We will review, in depth, the role of CK2 in leukemia and its mechanisms of tumorigenesis via phosphorylation of the tumor suppressor protein Ikaros. We will discuss both the importance of Ikaros in leukemia suppression and the restoration of Ikaros’ tumor suppressor function after CK2 inhibition by CX-4945 (a CK2-specific inhibitor). Results: CK2 is an oncogene that is overexpressed in hematological malignancies. In high risk Pre-B ALL, CK2 phosphorylates Ikaros tumor suppressor and promotes leukemogenesis. Inhibition of CK2 using CX4945 restores Ikaros function and leads to anti leukemic effects in vitro and in pre-clinical leukemia models. Conclusion: CK2 is an attractive target in treatment of various cancers. Currently only a few specific CK2 inhibitors are available. Preclinical studies using CK2 inhibitor, CX4945 in high risk pediatric leukemias have shown promising results and warrants further testing in other types of leukemia.

AB - Background: Casein kinase II (CK2) is a pro-oncogenic protein, which is emerging as a promising therapeutic target in cancer. Recent studies have revealed an important role for CK2 in tumorigenesis. High levels of CK2 are noted in many malignancies including leukemia. Use of CK2 inhibitors in various malignancies including breast, prostate, and lung cancer are being tested. Although many CK2 inhibitors exist, only a few have emerged as selective inhibitors that are potent and effective. CX-4945 is a selective, orallybioavailable small molecule inhibitor, which has shown encouraging results in pre-clinical models of leukemia. Methods: In this review we will elaborate on the structure and physiological function of the CK2 protein as well as its role in cancer. We will review, in depth, the role of CK2 in leukemia and its mechanisms of tumorigenesis via phosphorylation of the tumor suppressor protein Ikaros. We will discuss both the importance of Ikaros in leukemia suppression and the restoration of Ikaros’ tumor suppressor function after CK2 inhibition by CX-4945 (a CK2-specific inhibitor). Results: CK2 is an oncogene that is overexpressed in hematological malignancies. In high risk Pre-B ALL, CK2 phosphorylates Ikaros tumor suppressor and promotes leukemogenesis. Inhibition of CK2 using CX4945 restores Ikaros function and leads to anti leukemic effects in vitro and in pre-clinical leukemia models. Conclusion: CK2 is an attractive target in treatment of various cancers. Currently only a few specific CK2 inhibitors are available. Preclinical studies using CK2 inhibitor, CX4945 in high risk pediatric leukemias have shown promising results and warrants further testing in other types of leukemia.

UR - http://www.scopus.com/inward/record.url?scp=85013879073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013879073&partnerID=8YFLogxK

U2 - 10.2174/1381612822666161006154311

DO - 10.2174/1381612822666161006154311

M3 - Review article

VL - 23

SP - 95

EP - 107

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 1

ER -